FLNA — FILANA THERAPEUTICS, INC.

Nasdaq · Health Care · Pharmaceuticals · CIK 1069530 ·
Last close
$1.41
Market Cap
$68.11M
52W High
$2.49
52W Low
$1.16
ADV30
427,100
Next earnings
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -11,168,000 -10,331,000 108,367,000 86,573,000 40,226,000
Dec 2025 0 -14,288,000 -12,539,000 118,355,000 95,502,000 43,952,000
Sep 2025 0 -11,860,000 -10,807,000 129,733,000 106,080,000 48,165,000
Jun 2025 0 -45,392,000 -44,224,000 135,384,000 112,381,000 47,411,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-32,252,000
Investing CF
$-581,000
Financing CF
$-239,000
CapEx
$-575,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.88
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-496,084,000
Inventory
Receivables
$120,000
ST Investments
EBIT TTM
$-96,126,000
Pretax Income TTM
$-90,973,000
Interest Exp TTM
Analysts
1

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -96,126,000 -90,973,000 118,355,000 43,952,000 -32,252,000
Dec 2024 0 -142,279,000 -24,342,000 157,533,000 11,829,000 -116,929,000
Dec 2023 0 -107,333,000 -97,217,000 151,663,000 14,195,000 -82,025,000
Dec 2022 0 -81,482,000 -76,246,000 234,834,000 7,295,000 -77,514,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-31,017,000
OpCashFlow TTM
$0
Assets (Latest)
$234,834,000
Forward EPS

Peers — same industry

TickerNameMarket CapLastDaily %
RFL Rafael Holdings, Inc. $67.62M $1.32
MNOV MEDICINOVA INC $67.43M $1.37
IMMP IMMUTEP Ltd $66.86M $0.45
LIXT LIXTE BIOTECHNOLOGY HOLDINGS, INC. $69.96M $5.65
PMVP PMV Pharmaceuticals, Inc. $65.60M $1.23

News headlines (Yahoo Finance, 1h cache)

Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
2026-05-07 12:00 · Yahoo
Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII
2026-05-05 12:00 · Yahoo
Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data
2026-04-15 12:00 · Yahoo
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
2026-03-12 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.